HomepageBBN • SWX
add
Bellevue Group AG
Vorige slotkoers
CHF 13,45
Dag-range
CHF 12,70 - CHF 13,45
Jaar-range
CHF 11,05 - CHF 24,30
Beurswaarde
181,06 mln. CHF
Gem. volume
10,56K
Koers/winst
12,13
Dividendrendement
8,55%
Primaire beurs
SWX
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(CHF) | jun 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 18,41 mln. | -11,31% |
Bedrijfskosten | 13,73 mln. | -10,56% |
Netto inkomsten | 3,72 mln. | -7,22% |
Netto winstmarge | 20,18 | 4,61% |
Winst per aandeel | — | — |
EBITDA | — | — |
Effectief belastingtarief | 17,26% | — |
Balans
Totale activa
Totale passiva
(CHF) | jun 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 30,49 mln. | 100,63% |
Totale activa | 138,75 mln. | -4,69% |
Totale passiva | 22,05 mln. | -24,81% |
Totaal aandelenvermogen | 116,70 mln. | — |
Uitstaande aandelen | 13,20 mln. | — |
Koers-boekwaardeverhouding | 1,52 | — |
Rendement op activa | 10,71% | — |
Rendement op kapitaal | — | — |
Kasstroom
Nettomutatie in liquide middelen
(CHF) | jun 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 3,72 mln. | -7,22% |
Operationele kasstroom | 3,65 mln. | 137,31% |
Kasstroom uit beleggingen | — | — |
Kasstroom uit financiering | -8,10 mln. | 45,85% |
Nettomutatie in liquide middelen | -4,17 mln. | 83,13% |
Vrije kasstroom | — | — |
Over
Bellevue Group AG, headquartered in Zurich, is a listed investment management corporation from Switzerland. Bellevue Group consists of the subsidiaries Bellevue Asset Management, Bellevue Private Markets and StarCapital. It has 9,6 billion Swiss francs Assets Under Management Around 80% of clients assets are in healthcare investments. Bellevue Group is also active in alternative investments and private equity, including co-investments in private domestic small and medium-sized enterprises. In this business area, client assets under management were 1.0 billion francs as of mid-2021.
Bellevue Group is among the largest investors in the health care segment worldwide. It has subsidiaries in Germany, UK and USA, and is focusing on platform companies with products in phase two trials or later who preferably develop technologies that can be applied in multiple ways. One of the Bellevue Asset Management teams manages the BB Biotech investment company. The former investment company BB Medtech, which was converted into an equity fund at the end of September 2009, is also managed by Bellevue Asset Management. Wikipedia
CEO
Opgericht
1993
Website
Werknemers
88